ISSN:
1573-0646
Keywords:
elliptinium
;
Phase II study
;
breast cancer
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
,
Medicine
Notes:
Summary Eighteen patients with advanced measurable breast cancer were treated with elliptinium acetate 100 mg/m2 × 3 days every 3 weeks. Fourteen of these patients had failed prior chemotherapy. Two patients had an objective tumor response of greater than 4 weeks. Myelosuppression, renal insufficiency and thrombophlebitis were rarely encountered and alopecia was not seen at all. This study demonstrates that elliptinium has minimal activity in recurrent breast cancer with a favorable toxicity profile.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00170864
Permalink